HOWL Werewolf Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $44.83M | $56.43M | $41.78M | $53.76M | $35.27M |
| SG&A expense | $15.85M | $19.05M | $18.67M | $18.70M | $14.82M |
| Operating income | -$60.68M | -$73.59M | -$40.50M | -$56.06M | -$50.09M |
| Interest expense | $5.27M | $4.66M | $3.14M | $0 | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$60.82M | -$70.52M | -$37.37M | -$53.81M | -$49.98M |
| EBITDA | -$59.04M | -$71.78M | -$38.74M | -$54.95M | -$49.87M |
| EPS (basic) | -1.32 | -1.63 | -1.05 | -1.86 | -10.94 |
| EPS (diluted) | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 |
| Weighted avg. shares (diluted) | 46.81M | 43.86M | 35.65M | 28.86M | 18.45M |
| Balance sheet | |||||
| Cash & equivalents | $57.05M | $112.22M | $155.58M | $130.53M | $158.83M |
| Current assets | $58.59M | $113.07M | $138.37M | $140.20M | $161.07M |
| PP&E, net | $4.69M | $6.32M | $7.96M | $8.99M | $2.91M |
| Total assets | $69.40M | $126.93M | $174.83M | $160.25M | $179.25M |
| Current liabilities | $36.15M | $15.18M | $19.38M | $23.99M | $11.87M |
| Long-term debt | $32.09M | $32.09M | $40.00M | — | — |
| Total debt | $32.09M | $32.09M | $40.00M | — | — |
| Total liabilities | $44.59M | $53.54M | $63.46M | $37.91M | $26.46M |
| Shareholders' equity | $24.80M | $73.39M | $111.37M | $122.34M | $152.79M |
| Net debt | -$24.96M | -$80.13M | -$115.58M | — | — |
| Shares outstanding | 48.60M | 44.83M | 39.11M | 31.43M | 27.31M |
| Cash flow statement | |||||
| Operating cash flow | -$60.29M | -$56.19M | -$32.61M | -$40.60M | -$42.88M |
| Capital expenditure | $0 | $254,000 | $769,000 | $3.61M | $498,000 |
| Free cash flow | -$60.29M | -$56.44M | -$33.38M | -$44.21M | -$43.37M |
| Investing cash flow | $0 | -$254,000 | -$769,000 | -$3.61M | -$498,000 |
| Financing cash flow | $6.03M | $13.08M | $58.43M | $15.91M | $109.43M |
| Depreciation & amortization | $1.63M | $1.81M | $1.76M | $1.10M | $216,000 |
| Stock-based compensation | $6.25M | $8.83M | $8.01M | $7.40M | $4.09M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.